Who
Jay T. Backstrom
Director
Company insider
Files Form 4 as: Director, Agios Pharmaceuticals; Director, LAVA Therapeutics NV; Chief Executive Officer, Scholar Rock Holding; Director, Disc Medicine; EVP, Research and Development, Acceleron Pharma.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $1.8M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 2 Jan 2020
- Last trade
- 8 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 10 Jul 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,447 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,447 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,447 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,447 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 13 Nov 2025filed 17 Nov 2025 | LAVA Therapeutics NVoption or derivative | SEC FORM 4 Code D | —33,390 at $0.00 | filing |
| 8 Jul 2025filed 10 Jul 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,393 at $0.00 | filing |
| 8 Jul 2025filed 10 Jul 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,341 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —151,430 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —113,570 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $677K18,372 at $36.83 | filing |
| 13 Feb 2025filed 18 Feb 2025 | LAVA Therapeutics NVoption or derivative | SEC FORM 4 Code A | —33,390 at $0.00 | filing |
| 16 Jan 2025filed 21 Jan 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $986K22,308 at $44.20 | filing |
| 16 Feb 2024filed 20 Feb 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $183K11,614 at $15.74 | filing |
| 12 Feb 2024filed 13 Feb 2024 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —285,715 at $0.00 | filing |
| 12 Feb 2024filed 13 Feb 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —214,285 at $0.00 | filing |
| 13 Feb 2023filed 15 Feb 2023 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.